Hermès Made A Statement With Its Latest Results, And Ozempic Was Linked To A Lower Risk Of Alzheimer’s

from The Finimize Daily Brief · host Finimize

Hermès made a splashy statement with its latest results, outshining its luxury rivals, while Novo Nordisk’s popular weight-loss drug has been linked to a lowered risk of Alzheimer’s.Today’s stories:Hermès Came Out On Top With Its Latest Results, Leaving Luxury Rivals In The DustNovo Nordisk's Ozempic Drug Might Work Wonders For Mind As Well As BodyTry Finimize Premium

Episode metadata supplied by the publisher feed · Published Oct 25, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Hermès Made A Statement With Its Latest Results, And Ozempic Was Linked To A Lower Risk Of Alzheimer’s

0:00 5:25

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Finimize Daily Brief?

This episode is 5 minutes long.

When was this The Finimize Daily Brief episode published?

This episode was published on October 25, 2024.

Can I download this The Finimize Daily Brief episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!